Gamida Cell Presents New Data from Key Programs at 2017 ASH Annual Meeting
Nov 1, 2017 – Gamida Cell, a leading cellular and immune therapeutics company based in Jerusalem, announced that two oral presentations on new data from the
JLM-based Izun Pharmaceuticals Announces Positive Results from Phase 2 Double Blind Oral Mucositis Trial
Oct 11, 2017 – Izun Pharmaceuticals Corporation (“Izun”, “Company”, izunpharma.com), a clinical stage company focused on developing high efficacy products based on pharmaceutically active compounds
Chemo Group Invests in Modiin Based OCON Medical
Oct 17, 2017 – Ocon Medical has developed the IUB, a proprietary intrauterine platform made of a super-elastic alloy. Global healthcare giant Chemo Group has made
NovellusDx Elected to Pitch at the Galien Annual Event in New York this week
Oct 23, 2017 – NovellusDx has been selected again by the Galien Foundation organizing committee to pitch and participate in The Galien MedStartup Award event that will
CIITECH Sponsors Research Project on Cannabis-Based Therapy for Asthma at Hebrew U’s Center on Cannabinoid Research
Oct 24, 2017 – CIITECH, a UK-Israel cannabis biotech startup, announced today that it has selected to sponsor a research project with the Multidisciplinary Center on Cannabinoid
STK & Liddor Paving the way for New Biological Pipeline Production in Beit Shemesh
Oct 24 – 2017 – STK (Stockton), a leading company in the development and marketing of botanical based solutions for food protection and Lidorr Chemicals Ltd, an
Abigail Leichman, Israel21C, Reports on 10 of the Coolest Biotech Companies in Jerusalem
September 25, 2017 – Amazing new technologies for beating conditions including breast cancer, ALS and obesity are under development in Israel’s capital city. Jerusalem’s life-sciences cluster
$ 25 million investment to VC fund, Integra Holdings, who is bringing the Hebrew U’s Life Science Academic Excellence to market, led by Temasek (SIngapore)
September 27th, 2017 – Integra Holdings, an investment company exclusively focused on life science innovations originating from the Hebrew University, today announced the first closing
Korea Investment Partners to finance Jlm-based Enlivex Therapeutics’s lead compound for the prevention of Graft Vs Host Disease (GVHD)
Sept 20, 2017 – Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, announced today the closing of an $8 million equity financing round at a valuation of approximately $50
